Personalis, Inc. (PSNL)
PSNLNASDAQ-GMMedical Specialities
$15.82
-0.1350 (-0.85%) today
Regular session, Nov 10, 11:55 AM ET
- Market cap
- $1.71bn
- P/E
- –
- EPS, last 4 quarters
- $-1.17
- Dividend yield
- –
- Day range
- $15.81 to $16.07
- 52-week range
- $4.96 to $18.89
- Average volume
- 2.28m
- Previous close
- $15.95
Analysts
3 coveringHold0 buy, 3 hold, 0 sell
Targets a year out average $16.25, +2.8% from here
Earnings
Next report
Dec 2025
+16.1%
Mar 2026
-26.1%
Jun 2026
-20.0%
Sep 2026
–
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $17.34m | $15.47m | $22.36m | $25.60m |
| Gross profit | $1.90m | $281.0k | $4.74m | $6.57m |
| Operating income | -$25.27m | -$32.16m | -$33.59m | -$35.52m |
| Net income | -$23.81m | -$30.03m | -$31.68m | -$33.80m |
Last four quarters: revenue $80.77m, margin -147.7%, free cash flow -$107.69m
News
8 latest- Personalis, Inc. Reports Q3 Clinical Test Volume of 13,157 and Overall Revenue of $25.6 millionFintel · 6 days ago
- Noteworthy ETF Outflows: ARKG, TXG, PSNL, GHBNK Invest · Sep 16, 2026
- Tempus To Acquire Personalis, Expanding Precision Oncology Capabilities RTTNews · Jul 20, 2026
- Tempus AI To Buy Personalis For $16.25/Share; Stock Down Over 4% In Pre-Market RTTNews · Jul 20, 2026
- 5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & More RTTNews · Jul 19, 2026
- Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?The Motley Fool · Jun 4, 2026
- Thursday's ETF Movers: ARKG, XESBNK Invest · May 28, 2026
- Personalis Secure Medicare Coverage For NeXT Personal MRD Test In Immunotherapy Monitoring; Stock Up RTTNews · May 13, 2026
The company
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- personalis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.